Association of Systemic Immune-Inflammation Index with Non-Alcoholic Fatty Liver Disease: A Population-Based Cross-Sectional Study

Background The aim of this study was to explore the relationship between systemic immune-inflammation (SII) index with non-alcoholic fatty liver disease (NAFLD) in the general population of the United States (U.S.). Methods We conducted a cross-sectional study of subjects in the National Health and Nutrition Examination Survey 2017–2018. For the analysis of the association between SII index and risk of NAFLD, the restricted cubic spline (RCS) plot, we performed multivariable logistic regression models and subgroup analysis. In addition, generalized additive models with smooth functions were conducted for the relationship between the SII index and the ZJU index, the BARD score, and the NAFLD fibrosis score. Results There were a total of 1197 individuals in our study. Taking into account known confounding variables, compared with the lowest quartiles, the odds ratios with 95% confidence intervals for NAFLD across the quartiles were 0.923 (0.585, 1.455), 0.563 (0.351, 0.901), and 1.061 (0.669, 1.682), respectively. As shown by the RCS plot, the SII index was linked with NAFLD risk in a U-shaped pattern. Based on the results of subgroup analysis, SII index and NAFLD risk were U-curve correlated among participants in all age groups, male or female, with or without hypertension, with diabetes mellitus, and with a BMI of <30 or >30 kg/m2. The SII index was linearly positive with the ZJU index but negative with the NAFLD fibrosis score. However, the SII index and BARD score showed a trend of first decreasing, then increasing, and then decreasing. Conclusion The U-shaped relationships exist between SII index and risk of NAFLD, which highlighted that we should focus on the dynamic change of SII index.

[1]  Naifeng Liu,et al.  Association of Systemic Immune Inflammation Index with All-Cause, Cardiovascular Disease, and Cancer-Related Mortality in Patients with Cardiovascular Disease: A Cross-Sectional Study , 2023, Journal of inflammation research.

[2]  Jing Chen,et al.  Association of Systemic Immune Inflammation Index with Estimated Pulse Wave Velocity, Atherogenic Index of Plasma, Triglyceride-Glucose Index, and Cardiovascular Disease: A Large Cross-Sectional Study , 2023, Mediators of inflammation.

[3]  G. Aktas,et al.  A Novel Inflammatory Marker for the Diagnosis of Hashimoto’s Thyroiditis: Platelet-Count-to-Lymphocyte-Count Ratio , 2023, Diseases.

[4]  Lirui Wang,et al.  Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017–2018) and a controlled animal study , 2022, Nutrition & metabolism.

[5]  Guoyue Yuan,et al.  Weighted Gene Co-Expression Network Analysis of Immune Infiltration in Nonalcoholic Fatty Liver Disease. , 2022, Endocrine, metabolic & immune disorders drug targets.

[6]  Y. Li,et al.  Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015-2018 , 2022, Frontiers in Immunology.

[7]  F. Tacke,et al.  Treating inflammation to combat non-alcoholic fatty liver disease. , 2022, The Journal of endocrinology.

[8]  Nengqian Ma,et al.  Association between SII and hepatic steatosis and liver fibrosis: A population-based study , 2022, Frontiers in Immunology.

[9]  Wenchen Li,et al.  Predictive Value of the Systemic Immune Inflammation Index for Adverse Outcomes in Patients With Acute Ischemic Stroke , 2022, Frontiers in Neurology.

[10]  Yi Luan,et al.  Systemic Immune-Inflammation Index Predicts Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Cross-Sectional Study , 2022, Frontiers in Medicine.

[11]  K. Cusi,et al.  A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.

[12]  H. Tilg,et al.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity , 2021, Nature Metabolism.

[13]  G. Ioannou.  Epidemiology and risk-stratification of NAFLD-associated HCC. , 2021, Journal of hepatology.

[14]  Y. Feng,et al.  Association of Systemic Immune-Inflammation Index With Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study , 2021, Frontiers in Cardiovascular Medicine.

[15]  G. Aktas.  Hematological predictors of novel Coronavirus infection. , 2021, Revista da Associacao Medica Brasileira.

[16]  M. Roden,et al.  The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments , 2021, Nature Reviews Gastroenterology & Hepatology.

[17]  N. Méndez-Sánchez,et al.  Obesity and Gallstones , 2021, Visceral Medicine.

[18]  G. Aktas,et al.  The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. , 2021, Revista da Associacao Medica Brasileira.

[19]  Xuchu Wang,et al.  Elevated systemic immune inflammation index level is associated with disease activity in ulcerative colitis patients. , 2021, Clinica chimica acta; international journal of clinical chemistry.

[20]  S. Ikramuddin,et al.  Nonalcoholic Steatohepatitis: A Review. , 2020, JAMA.

[21]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[22]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[23]  Pengfei Diao,et al.  Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection , 2018, Journal of Translational Medicine.

[24]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[25]  C. Hetz,et al.  Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.

[26]  Wan-Hai Wang,et al.  Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis , 2018, Journal of Cancer.

[27]  A. Feldstein,et al.  Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.

[28]  L. Boccuto,et al.  A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. , 2018, Journal of gastrointestinal and liver diseases : JGLD.

[29]  Yu-suo Tong,et al.  Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer , 2017, Journal of Translational Medicine.

[30]  M. Zhang,et al.  Inflammasome activation involved in early inflammation reaction after liver transplantation. , 2017, Immunology letters.

[31]  C. Zou,et al.  Relationship between immune parameters and non-alcoholic fatty liver disease in obese children , 2017, Indian Pediatrics.

[32]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[33]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[34]  Alexis M. Kalergis,et al.  Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.

[35]  Youming Li,et al.  ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population , 2015, Scientific Reports.

[36]  J. Everhart,et al.  Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey , 2015, Alimentary pharmacology & therapeutics.

[37]  W. Guo,et al.  Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[38]  Yechiam Ostchega,et al.  Health and nutrition examination survey plan and operations, 1999-2010 , 2013 .

[39]  K. Takeda,et al.  Postmortem computed tomography is an informative approach for prevention of sudden unexpected natural death in the elderly , 2010, Risk management and healthcare policy.

[40]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[41]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[42]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[43]  Jian-Gao Fan,et al.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. , 2003, World journal of gastroenterology.

[44]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[45]  G. Jacquemin.  [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[46]  G. Aktas,et al.  Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios are useful in differentiation of thyroid conditions with normal and increased uptake , 2021 .

[47]  G. Aktas,et al.  Irritable bowel syndrome is associated with novel inflammatory markers derived from hemogram parameters , 2020 .

[48]  G. Aktas,et al.  Diabetes control could through platelet-to-lymphocyte ratio in hemograms. , 2019, Revista da Associacao Medica Brasileira.

[49]  J. Everhart,et al.  Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. , 2003, Gastroenterology.

[50]  E. Zafrani.  Non-alcoholic fatty liver disease: an emerging pathological spectrum , 2003, Virchows Archiv.

[51]  C. Newgard,et al.  Metabolic coupling factors in pancreatic beta-cell signal transduction. , 1995, Annual review of biochemistry.